2-stage design with interim sample size estimation [Two-Stage / GS Designs]

posted by Jack Homepage – Lancaster, United Kingdom, 2010-10-26 18:26 (3572 d 23:24 ago) – Posting: # 6083
Views: 10,433

Dear d_labes,

the reason I call this a one-stage design is that I would not formally test for equivalence at the time were one does the sample size re-estimation. Hence one would not need to spend any alpha at this time (as no testing is done and hence the EMA guide is not relevant) and hence no risk of the awkward situation that one could have to stop the trial early.

This is also the reason why doing the sample size re-estimation in a blinded fashion can make sense as using unblinded data will question the one-stage design.

As for the question: "Can we expect to prove BE with a Nmax of 120 subjects with some pre-specified power?"

I dont really see the problem there. You are not arriving at a test decision about BE if you decide to stop because you would need more resources than you have and hence it is not impacting your type-I-error. Having such a rule has therefore no bearing on the formal testing.

Finally, I agree that results from superiority trials will not apply directly they do, however, often contain useful ideas how one can tackle a problem in equivalence from first principle.

Complete thread:

Activity
 Admin contact
20,977 posts in 4,374 threads, 1,460 registered users;
online 20 (0 registered, 20 guests [including 14 identified bots]).
Forum time: Friday 17:51 CEST (Europe/Vienna)

When someone says his conclusions are objective,
he means that they are based on prejudices
which many other people share.    Celia Green

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5